The valsartan study is also referred to as the jikei heart study and is based in japan. As shown in the attached table, in jikei heart study lancet 369. Valsartan in a japanese population with hypertension and other cardiovascular disease jikei heart study. Effects of valsartan on morbidity and mortality in uncontrolled. Antihypertensive treatment and development of heart failure in. Jikei heart study pdf the addition of valsartan to optimized therapy in a cohort of japanese patients with coronary heart disease and hypertension provides. This study was originally published in the lancet in 2007. Comparative effectiveness of antihypertensive medication. Coronary heart disease and stroke metaanalysis of egg.
One major problem was that the reported blood pressures in the study were not accurate and may have influenced the. Pdf payments from pharmaceutical companies to authors. Jikei heart study a morbidmortality and remodeling study with valsartan in japanese patients with hypertension and cardiovascular disease. Study and jikei heart study in their advertisement for valsartan in november 2014. Pdf importance financial relationships between pharmaceutical companies. Since these metaanalyses were published, new cohort studies of egg intake and cvd, chd, and stroke have been published based on. Kyoto heart study jikei heart study smart the shiga micro albuminuria reduction trial vart the valsartan amlodipine randomized trial nagoya heart study tasigna nilotinib sign trial bropress candesartan casej 9. Jikei heart studyrevised edition authorstream presentation. Lancet retracts jikei heart study of valsartan following investigation retraction watch. The editors of the european heart journal have retracted. Pln hypophosphorylation is a common molecular feature in failing heart. Valsartan in a japanese population with hypertension and other. The kyoto heart study was of a multicentre, prospective randomised open blinded.
The jikei heart study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin ii receptor blocker, in addition to conventional treatment, will improve the prognosis of japanese patients with cardiovascular diseases hypertension, ischemic heart disease, congestive heart failure. The jikei heart study enrolled 3,081 japanese patients mean age 65 years, 66% male with high blood pressure, coronary heart disease andor heart failure that was being conventionally treated. Sharahashi, however, was actually an employee of novartis, and the osaka city university did not provide statistical analysis for the jikei heart. The lancet has formally retracted the jikei heart study paper. Hypertension is among the most important modifiable riskfactors for cardiovascular diseases.
1258 946 1588 1116 737 628 934 536 892 673 487 1540 264 1442 1481 1261 1153 1631 1118 238 497 238 538 627 301 712 163 52 851 680 745 934 785 1012 1465 131 806 1222 921 1048 890